Companies
Rise of weight-loss drugs offers opportunity, including for Glanbia’s SlimFast
Hugh McGuire says the nutritional giant’s range of protein products could see increased demand
The widespread use of powerful weight-loss drugs in the United States offers an opportunity for Glanbia, according to Hugh McGuire, the new chief executive.
The use of GLP-1 agonists drugs, which help people lose more than 10 per cent of their body weight, has increased rapidly in the past year with Ozempic maker Novo Nordisk and Mounjaro producer Eli Lilly leading the race.
McGuire, who formally took up the helm of nutritional giant Glanbia at ...
